Advertisement

Obesity and Prostate Cancer

  • Yin Cao
  • Edward GiovannucciEmail author
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 208)

Abstract

Prostate cancer is a complex, heterogeneous disease. Factors related to detection, particularly PSA screening, further increase heterogeneity in the manifestation of the disease. It is thus not possible to provide a simple summary of the relationship between obesity and prostate cancer. Findings on obesity, often defined using body mass index (BMI), and total prostate cancer risk have been mixed; however, obesity is relatively consistently associated with a higher risk of aggressive prostate cancer, with aggressiveness defined in various ways (e.g., advanced stage, fatal, poorer prognosis in men with prostate cancer). Many methodologic issues (e.g., influence of PSA screening, detection bias and treatment) need to be thoroughly considered in both existing and future etiologic and prognostic research. Biological mechanisms supporting the link are under investigation, but may involve insulin and IGF axis, sex steroid hormones and alterations in metabolism. Some promising data suggest that molecular sub-types of prostate cancer may offer insights into etiology, but further study is required. A full evaluation of body fatness and weight change over the life course would not only provide insights to the underlying mechanisms but also allow more effective interventions.

Keywords

Obesity Prostate cancer Prostate-specific antigen screening Heterogenity 

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase No. 11. IARC Press, LyonGoogle Scholar
  2. 2.
    Cancer Facts & Figures 2015 (2015). American Cancer Society, AtlantaGoogle Scholar
  3. 3.
    Chu KC, Tarone RE, Freeman HP (2003) Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97(6):1507–1516. doi: 10.1002/cncr.11212 CrossRefPubMedGoogle Scholar
  4. 4.
    Jahn JL, Giovannucci EL, Stampfer MJ (2015) The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer J Int Cancer 137(12):2795–2802. doi: 10.1002/ijc.29408 CrossRefGoogle Scholar
  5. 5.
    Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC (2007) Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer J Int Cancer 121(7):1571–1578. doi: 10.1002/ijc.22788 CrossRefGoogle Scholar
  6. 6.
    Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 4(4):486–501. doi: 10.1158/1940-6207.CAPR-10-0229 CrossRefGoogle Scholar
  7. 7.
    Discacciati A, Orsini N, Wolk A (2012) Body mass index and incidence of localized and advanced prostate cancer—a dose-response meta-analysis of prospective studies. Ann Oncol (Official Journal of the European Society for Medical Oncology/ESMO) 23(7):1665–1671. doi: 10.1093/annonc/mdr603 CrossRefGoogle Scholar
  8. 8.
    MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control (CCC) 17(8):989–1003. doi: 10.1007/s10552-006-0049-z CrossRefGoogle Scholar
  9. 9.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578. doi: 10.1016/S0140-6736(08)60269-X CrossRefPubMedGoogle Scholar
  10. 10.
    Fowke JH, McLerran DF, Gupta PC, He J, Shu XO, Ramadas K, Tsugane S, Inoue M, Tamakoshi A, Koh WP, Nishino Y, Tsuji I, Ozasa K, Yuan JM, Tanaka H, Ahn YO, Chen CJ, Sugawara Y, Yoo KY, Ahsan H, Pan WH, Pednekar M, Gu D, Xiang YB, Sauvaget C, Sawada N, Wang R, Kakizaki M, Tomata Y, Ohishi W, Butler LM, Oze I, Kim DH, You SL, Park SK, Parvez F, Chuang SY, Chen Y, Lee JE, Grant E, Rolland B, Thornquist M, Feng Z, Zheng W, Boffetta P, Sinha R, Kang D, Potter JD (2015) Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol 182(5):381–389. doi: 10.1093/aje/kwv089 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chia SJ, Tang WY, Elnatan J, Yap WM, Goh HS, Smith DR (2000) Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer 83(6):761–768. doi: 10.1054/bjoc.2000.1355 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC, Platz EA (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila) 4(4):544–551. doi: 10.1158/1940-6207.CAPR-10-0257 CrossRefGoogle Scholar
  13. 13.
    Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA (2013) Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16(1):62–66. doi: 10.1038/pcan.2012.32 CrossRefPubMedGoogle Scholar
  14. 14.
    Tomaszewski JJ, Richman EL, Sadetsky N, O’Keefe DS, Carroll PR, Davies BJ, Chan JM (2014) Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE. J Urol 191(4):971–976. doi: 10.1016/j.juro.2013.09.065 CrossRefPubMedGoogle Scholar
  15. 15.
    Moller E, Wilson KM, Batista JL, Mucci LA, Balter K, Giovannucci E (2015) Body size across the life course and prostate cancer in the health professionals follow-up study. Int J Cancer J Int Cancer. doi: 10.1002/ijc.29842 Google Scholar
  16. 16.
    Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):s843–s857PubMedGoogle Scholar
  17. 17.
    Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, Lenzi A, Giugliano D (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 36(2):132–139. doi: 10.1007/BF03346748 CrossRefPubMedGoogle Scholar
  18. 18.
    Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjonneland A, Severinsen MT, Overvad K, Rohrmann S, Kaaks R, Trichopoulou A, Zoi G, Trichopoulos D, Pala V, Palli D, Tumino R, Sacerdote C, Bueno-De-Mesquita HB, May A, Manjer J, Wallstrom P, Stattin P, Hallmans G, Buckland G, Larranaga N, Chirlaque MD, Martinez C, Cornejo MLR, Ardanaz E, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E (2008) Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidem Biomar 17(11):3252–3261. doi: 10.1158/1055-9965.Epi-08-0609 Google Scholar
  19. 19.
    MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG (2003) Body size and composition and prostate cancer risk. Cancer Epidem Biomar 12(12):1417–1421Google Scholar
  20. 20.
    Ohwaki K, Endo F, Hattori K (2015) Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Cancer 51(5):604–609. doi: 10.1016/j.ejca.2015.01.003 CrossRefPubMedGoogle Scholar
  21. 21.
    Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, Hu FB, Giovannucci EL (2015) Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst 107(2). doi: 10.1093/jnci/djv088
  22. 22.
    Bonn SE, Wiklund F, Sjolander A, Szulkin R, Stattin P, Holmberg E, Gronberg H, Balter K (2014) Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control (CCC) 25(8):933–943. doi: 10.1007/s10552-014-0393-3 CrossRefGoogle Scholar
  23. 23.
    Sutcliffe S, Colditz GA (2013) Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer 13(3):208–518. doi: 10.1038/nrc3434 Google Scholar
  24. 24.
    Littman AJ, White E, Kristal AR (2007) Anthropometrics and prostate cancer risk. Am J Epidemiol 165(11):1271–1279. doi: 10.1093/aje/kwm013 CrossRefPubMedGoogle Scholar
  25. 25.
    Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A (2011) Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 105(7):1061–1068. doi: 10.1038/bjc.2011.319 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95(16):1240–1244CrossRefPubMedGoogle Scholar
  27. 27.
    Robinson WR, Stevens J, Gammon MD, John EM (2005) Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol 161(12):1107–1114. doi: 10.1093/aje/kwi150 CrossRefPubMedGoogle Scholar
  28. 28.
    Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA (2000) Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 151(6):541–549CrossRefPubMedGoogle Scholar
  29. 29.
    Barba M, Terrenato I, Schunemann HJ, Fuhrman B, Sperati F, Teter B, Gallucci M, D’Amato A, Muti P (2008) Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study. Urology 72(1):183–187. doi: 10.1016/j.urology.2007.09.065 CrossRefPubMedGoogle Scholar
  30. 30.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1997) Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 6(8):557–563Google Scholar
  31. 31.
    Aarestrup J, Gamborg M, Cook MB, Sorensen TI, Baker JL (2014) Childhood body mass index and the risk of prostate cancer in adult men. Br J Cancer 111(1):207–212. doi: 10.1038/bjc.2014.266 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, Xie T, Gao YT (2000) Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 9(12):1335–1341Google Scholar
  33. 33.
    Li J, Djenaba JA, Soman A, Rim SH, Master VA (2012) Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001–2007. Prostate Cancer 2012:691380. doi: 10.1155/2012/691380 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Satia JA, Galanko JA (2007) Demographic, behavioral, psychosocial, and dietary correlates of cancer screening in African Americans. J Health Care Poor Underserved 18(4 Suppl):146–164CrossRefPubMedGoogle Scholar
  35. 35.
    Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK (2006) Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175(2):500–504; discussion 504. doi: 10.1016/S0022-5347(05)00162-X Google Scholar
  36. 36.
    Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298(19):2275–2280. doi: 10.1001/jama.298.19.2275 CrossRefPubMedGoogle Scholar
  37. 37.
    Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL Jr, Team PP (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 18(3):748–751. doi: 10.1158/1055-9965.EPI-08-0938 CrossRefGoogle Scholar
  38. 38.
    Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684. doi: 10.1002/cncr.22443 CrossRefPubMedGoogle Scholar
  39. 39.
    Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047. doi: 10.1016/S1470-2045(08)70235-3 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 22(3):446–453. doi: 10.1200/JCO.2004.04.181 CrossRefGoogle Scholar
  41. 41.
    Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, Sexton WJ, Soderdahl DW, Donahue TF, Foley JP, Chung AK, McLeod DG (2004) Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22(3):439–445CrossRefPubMedGoogle Scholar
  42. 42.
    Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ (2012) Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol 62(5):910–916. doi: 10.1016/j.eururo.2012.08.015 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Millender LE, Aubin M, Pouliot J, Shinohara K, Roach M 3rd (2004) Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 59(1):6–10. doi: 10.1016/j.ijrobp.2003.12.027 CrossRefPubMedGoogle Scholar
  44. 44.
    Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ, Search Database Study G (2004) Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 172(2):520–524. doi: 10.1097/01.ju.0000135302.58378.ae Google Scholar
  45. 45.
    Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, consortium P, Lathrop M, Smith GD, Martin RM (2015) The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control (CCC) 26(11):1603–1616. doi: 10.1007/s10552-015-0654-9 Google Scholar
  46. 46.
    Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Investig 106(4):473–481. doi: 10.1172/JCI10842 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hsing AW, Chua S Jr, Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93(10):783–789CrossRefPubMedGoogle Scholar
  48. 48.
    Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279. doi: 10.1093/jnci/djp260 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA (2004) Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 63(2):253–258. doi: 10.1016/j.urology.2003.09.060 CrossRefPubMedGoogle Scholar
  50. 50.
    Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103(1):76–84. doi: 10.1002/cncr.20727 CrossRefPubMedGoogle Scholar
  51. 51.
    Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92(23):1910–1917CrossRefPubMedGoogle Scholar
  52. 52.
    Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, Platz EA (2014) Association of C-peptide and leptin with prostate cancer incidence in the health professionals follow-up study. Cancer Causes Control (CCC) 25(5):625–632. doi: 10.1007/s10552-014-0369-3 CrossRefGoogle Scholar
  53. 53.
    Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, Hallmans G, Kaaks R, Stattin P (2007) Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer J Int Cancer 120(12):2678–2686. doi: 10.1002/ijc.22587 CrossRefGoogle Scholar
  54. 54.
    Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak MD, Whittemore AS, Wu AH, Gallagher RP (2007) Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 16(10):2164–2165. doi: 10.1158/1055-9965.EPI-07-0495 CrossRefGoogle Scholar
  55. 55.
    Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, Clavel-Chapelon F, van Gils CH, van Noord PA, Peeters PH, Bueno-de-Mesquita HB, Nagel G, Linseisen J, Lahmann PH, Boeing H, Palli D, Sacerdote C, Panico S, Tumino R, Sieri S, Dorronsoro M, Quiros JR, Navarro CA, Barricarte A, Tormo MJ, Gonzalez CA, Overvad K, Paaske Johnsen S, Olsen A, Tjonneland A, Travis R, Allen N, Bingham S, Khaw KT, Stattin P, Trichopoulou A, Kalapothaki V, Psaltopoulou T, Casagrande C, Riboli E, Kaaks R (2006) Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. Int J Obes 30(11):1623–1631. doi: 10.1038/sj.ijo.0803324 CrossRefGoogle Scholar
  56. 56.
    Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB (1997) Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord (Journal of the International Association for the Study of Obesity) 21(5):355–359CrossRefGoogle Scholar
  57. 57.
    Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, Dossus L, Micheli A, Arslan A, Lenner P, Shore RE, Krogh V, Koenig KL, Riboli E, Berrino F, Hallmans G, Stattin P, Toniolo P, Kaaks R (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol/Eur Fed Endocr Soc 150(2):161–171CrossRefGoogle Scholar
  58. 58.
    Frystyk J, Brick DJ, Gerweck AV, Utz AL, Miller KK (2009) Bioactive insulin-like growth factor-I in obesity. J Clin Endocrinol Metab 94(8):3093–3097. doi: 10.1210/jc.2009-0614 CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer J Int Cancer 124(10):2416–2429. doi: 10.1002/ijc.24202 CrossRefGoogle Scholar
  60. 60.
    Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149(7):461–471, W483–W468Google Scholar
  61. 61.
    Price AJ, Allen NE, Appleby PN, Crowe FL, Travis RC, Tipper SJ, Overvad K, Gronbaek H, Tjonneland A, Johnsen NF, Rinaldi S, Kaaks R, Lukanova A, Boeing H, Aleksandrova K, Trichopoulou A, Trichopoulos D, Andarakis G, Palli D, Krogh V, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Arguelles MV, Sanchez MJ, Chirlaque MD, Barricarte A, Larranaga N, Gonzalez CA, Stattin P, Johansson M, Khaw KT, Wareham N, Gunter M, Riboli E, Key T (2012) Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 21(9):1531–1541. doi: 10.1158/1055-9965.EPI-12-0481-T CrossRefGoogle Scholar
  62. 62.
    Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL (2015) Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer J Int Cancer 136(10):2418–2426. doi: 10.1002/ijc.29295 CrossRefGoogle Scholar
  63. 63.
    Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E (2011) Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the health professionals follow-up study 1993–2004. Int J Cancer J Int Cancer 128(3):660–667. doi: 10.1002/ijc.25381 CrossRefGoogle Scholar
  64. 64.
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW (2001) Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 10(5):421–427Google Scholar
  65. 65.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224. doi: 10.1056/NEJMoa030660 CrossRefPubMedGoogle Scholar
  66. 66.
    Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF (2014) 5alpha-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 174(8):1301–1307. doi: 10.1001/jamainternmed.2014.1600 CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG (2006) Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 15(1):86–91. doi: 10.1158/1055-9965.EPI-05-0633 CrossRefGoogle Scholar
  68. 68.
    Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 14(5):1262–1269. doi: 10.1158/1055-9965.EPI-04-0371 CrossRefGoogle Scholar
  69. 69.
    Endogenous H, Prostate Cancer Collaborative G, Roddam AW, Allen NE, Appleby P, Key TJ (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100(3):170–183. doi: 10.1093/jnci/djm323 CrossRefGoogle Scholar
  70. 70.
    Hautanen A (2000) Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metabol Disord (Journal of the International Association for the Study of Obesity) 24(Suppl 2):S64–S70CrossRefGoogle Scholar
  71. 71.
    Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47(1):52–58. doi: 10.1002/pros.1046 CrossRefPubMedGoogle Scholar
  72. 72.
    Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA (2005) Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173(6):1935–1937. doi: 10.1097/01.ju.0000158040.33531.e7 CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T (2003) Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169(5):1670–1675. doi: 10.1097/01.ju.0000062674.43964.d0 CrossRefPubMedGoogle Scholar
  74. 74.
    Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 265(5):618–621CrossRefPubMedGoogle Scholar
  75. 75.
    Ribeiro M, Ruff P, Falkson G (1997) Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20(6):605–608CrossRefPubMedGoogle Scholar
  76. 76.
    Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, DuPre N, Giovannucci E, Mucci LA (2014) Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol 65(4):683–689. doi: 10.1016/j.eururo.2013.01.003 CrossRefPubMedGoogle Scholar
  77. 77.
    Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev (A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology) 15(11):2056–2062. doi: 10.1158/1055-9965.EPI-06-0410 CrossRefGoogle Scholar
  78. 78.
    Cai H, Xu Z, Xu T, Yu B, Zou Q (2015) Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes/Metab Res Rev 31(4):336–343. doi: 10.1002/dmrr.2582 CrossRefGoogle Scholar
  79. 79.
    Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648. doi: 10.1126/science.1117679 CrossRefPubMedGoogle Scholar
  80. 80.
    Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA (2013) Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 105(24):1881–1890. doi: 10.1093/jnci/djt332 CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Hunt DA, Lane HM, Zygmont ME, Dervan PA, Hennigar RA (2007) MRNA stability and overexpression of fatty acid synthase in human breast cancer cell lines. Anticancer Res 27(1A):27–34PubMedGoogle Scholar
  82. 82.
    Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28(6):686–692CrossRefPubMedGoogle Scholar
  83. 83.
    Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M (2010) Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol (Official Journal of the American Society of Clinical Oncology) 28(25):3958–3964. doi: 10.1200/JCO.2009.27.0793 CrossRefGoogle Scholar
  84. 84.
    Campa D, McKay J, Sinilnikova O, Husing A, Vogel U, Hansen RD, Overvad K, Witt PM, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Rohrmann S, Chang-Claude J, Boeing H, Fisher E, Trichopoulou A, Trichopoulos D, Palli D, Villarini A, Sacerdote C, Mattiello A, Tumino R, Peeters PH, van Gils CH, Bas Bueno-de-Mesquita H, Lund E, Chirlaque MD, Sala N, Suarez LR, Barricarte A, Dorronsoro M, Sanchez MJ, Lenner P, Hallmans G, Tsilidis K, Bingham S, Khaw KT, Gallo V, Norat T, Riboli E, Rinaldi S, Lenoir G, Tavtigian SV, Canzian F, Kaaks R (2009) Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. Breast Cancer Res Treat 118(3):565–574. doi: 10.1007/s10549-009-0347-8 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Clinical and Translational Epidemiology UnitMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Department of NutritionHarvard T. H. Chan School of Public HealthBostonUSA
  3. 3.Department of EpidemiologyHarvard T. H. Chan School of Public HealthBostonUSA
  4. 4.Channing Division of Network MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations